ArticleTargeted oncology2026
One-Week Inflammatory Kinetics After First-Line Nivolumab Plus Ipilimumab in Metastatic Renal Cell Carcinoma: A Multicenter Landmark Analysis.
Article in Targeted oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFirst-line nivolumab plus ipilimumab can produce durable survival in metastatic renal cell carcinoma, yet some patients experience early progression or rapid clinical deterioration before first scheduled imaging. Because radiologic response assessment is typically unavailable until approximately 12 weeks, clinically accessible signals during this pre-imaging interval are needed.
objectiveWe aimed to evaluate whether early changes in blood-based inflammatory biomarkers at predefined post-treatment landmarks were associated with overall survival and to determine which biomarker showed the most consistent early prognostic signal.
methodsIn this multicenter retrospective cohort study across eight Japanese institutions, 219 patients with metastatic renal cell carcinoma treated with first-line nivolumab plus ipilimumab were analyzed. Predefined landmark analyses at 1 week, 1 month, and 3 months compared six blood-based inflammatory biomarkers using restricted cubic splines with multiple imputation. Overall survival was the primary endpoint.
resultsThe 1-week landmark showed the most consistent association with overall survival. Among six biomarkers, change in pan-immune-inflammation value showed the most reproducible pattern. Among 183 patients with paired baseline and 1-week pan-immune-inflammation value data, PIV-BOOST, defined as any pan-immune-inflammation value increase (> 0%) from baseline, was observed in 110 patients (60.1%) and was independently associated with improved overall survival (adjusted hazard ratio 0.60, 95% confidence interval 0.39-0.92; p = 0.018).
conclusionsOne-week inflammatory kinetics provided early prognostic information before first scheduled imaging in first-line nivolumab plus ipilimumab-treated metastatic renal cell carcinoma. A simple direction-of-change rule for pan-immune-inflammation value may complement baseline risk assessment; however, prospective external validation is required before clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.